Versartis, a biotech developing long-acting treatments for growth hormone deficiency, filed on Tuesday with the SEC to raise up to $80 million in an initial public offering. The Redwood City, CA-based company was founded in 2008. Versartis initially filed confidentially on January 10, 2014. Morgan Stanley and Citi are the joint bookrunners on the deal. No pricing terms were disclosed.
